GlassScriptPhysician profile
Hetal P Patel
NPI 1508068685
$7,183.02
in general payments reported to CMS, 2019-2025
29 companies · $1,270 in 2025
The $1,270 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $553 · 2021: $1,172 · 2022: $898 · 2023: $1,146 · 2024: $1,468 · 2025: $1,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,884.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,125.42 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,068.58 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $996.75 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $495.51 | 2019-2025 | Lybalvi, Aristada |
| Teva Pharmaceuticals USA, INC. | $482.02 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $424.38 | 2019-2025 | Spravato |
| Lundbeck LLC | $390.09 | 2019-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $385.81 | 2023-2025 | Qelbree, Qelbree |
| Allergan, INC. | $301.55 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $243.72 | 2019-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $213.35 | 2019-2021 | |
| Corium, LLC | $117.05 | 2022-2024 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $114.81 | 2022 | |
| Vanda Pharmaceuticals INC. | $107.98 | 2025 | Fanapt |
| Neurocrine Biosciences, INC. | $86.00 | 2023-2025 | Ingrezza |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $83.80 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $83.68 | 2022-2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $74.02 | 2024-2025 | Cobenfy |
| Indivior INC. | $55.31 | 2023-2024 | Perseris |
| Collegium Pharmaceutical, INC. | $48.11 | 2025 | Jornay Pm |
| Owp Pharmaceuticals, INC. | $46.38 | 2019-2022 | |
| Tris Pharma INC | $45.53 | 2022-2024 | Dyanavel Xr |
| Shire North American Group INC | $45.08 | 2019 | |
| Axsome Therapeutics, INC. | $36.60 | 2025 | Auvelity |
| Neos Therapeutics, LP | $28.41 | 2019 | |
| Bausch Health US, LLC | $27.42 | 2022 | |
| Ironshore Pharmaceuticals INC. | $23.35 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.98 | 2025 | |
| Validus Pharmaceuticals LLC | $15.33 | 2025 | Raldesy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hetal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.